Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Hanada Website

Ken-ichi Hanada, M.D., Ph.D.

Selected Publications

1)  Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR, Mixon A, Farid S, Dudley ME, Hanada K, Almeida JR, Darko S, Douek DC, Yang JC, Rosenberg SA.
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors.
J. Clin. Invest. [Epub ahead of print], 2014.
[Journal]
2)  Hanada K, Restifo NP.
Double or nothing on cancer immunotherapy.
Nat. Biotechnol. 31: 33-4, 2013.
[Journal]
3)  Abate-Daga D, Hanada K, Davis JL, Yang JC, Rosenberg SA, Morgan RA.
Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes.
Blood. 122: 1399-410, 2013.
[Journal]
4)  Tikhonova AN, Van Laethem F, Hanada K, Lu J, Pobezinsky LA, Hong C, Guinter TI, Jeurling SK, Bernhardt G, Park JH, Yang JC, Sun PD, Singer A.
aß T cell receptors that do not undergo major histocompatibility complex-specific thymic selection possess antibody-like recognition specificities.
Immunity. 36: 79-91, 2012.
[Journal]
5)  Wang QJ, Hanada K, Robbins PF, Li YF, Yang JC.
Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma.
Cancer Res. 72: 6119-29, 2012.
[Journal]
6)  Dalet A, Robbins PF, Stroobant V, Vigneron N, Li YF, El-Gamil M, Hanada K, Yang JC, Rosenberg SA, Van den Eynde BJ.
An antigenic peptide produced by reverse splicing and double asparagine deamidation.
Proc. Natl. Acad. Sci. U.S.A. 108: E323-31, 2011.
[Journal]
7)  Wang QJ, Hanada K, Feldman SA, Zhao Y, Inozume T, Yang JC.
Development of a genetically-modified novel T-cell receptor for adoptive cell transfer against renal cell carcinoma.
J. Immunol. Methods. 366: 43-51, 2011.
[Journal]
8)  Hanada K, Wang QJ, Inozume T, Yang JC.
Molecular identification of an MHC-independent ligand recognized by a human {alpha}/{beta} T-cell receptor.
Blood. 117: 4816-25, 2011.
[Journal]
9)  Frankel TL, Burns W, Riley J, Morgan RA, Davis JL, Hanada K, Quezado M, Rosenberg SA, Royal RE.
Identification and characterization of a tumor infiltrating CD56(+)/CD16 (-) NK cell subset with specificity for pancreatic and prostate cancer cell lines.
Cancer Immunol. Immunother. 59: 1757-69, 2010.
[Journal]
10)  Inozume T, Hanada K, Wang QJ, Ahmadzadeh M, Wunderlich JR, Rosenberg SA, Yang JC.
Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells.
J. Immunother. 33: 956-64, 2010.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 4/9/2014.